CriticalCalcineurin inhibitor (immunosuppressant)×Atypical antipsychotic – indole derivative
Updated · Methodology
Mechanism
Ziprasidone itself causes mild to moderate, dose-dependent QT prolongation (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tacrolimus can also prolong the QT interval and cause torsade de pointes ventricular tachycardia (tacrolimus SmPC, AEMPS, and label, US Food and Drug Administration, FDA). No studies have been done with ziprasidone and other QT-prolonging drugs, and an additive effect on QT cannot be excluded (ziprasidone SmPC, AEMPS, and label, FDA). CYP3A4 metabolises tacrolimus, and tacrolimus itself inhibits this enzyme, so it may affect the metabolism of drugs that go through it (tacrolimus SmPC, AEMPS). However, CYP enzymes handle less than a third of ziprasidone clearance. Even the strong CYP3A4 inhibitor ketoconazole raised ziprasidone levels by less than 40%, without further prolongation of the heart-rate-corrected QT interval (QTc) (ziprasidone SmPC, AEMPS, and label, FDA). Ziprasidone has little inhibitory effect on the major CYP enzymes (FDA ziprasidone label), and the documents give no data on how these two drugs change each other's levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). A ventricular arrhythmia causes palpitations, dizziness or fainting and can lead to cardiac arrest. Palpitations, vertigo, fainting or seizures during ziprasidone treatment may signal a malignant arrhythmia. Post-marketing reports describe infrequent cases of torsade de pointes in people taking ziprasidone who had several risk factors (ziprasidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With tacrolimus, ventricular arrhythmias and cardiac arrest are uncommon, and QT prolongation and torsade de pointes are very rare (tacrolimus SmPC, AEMPS). The risk of arrhythmia is higher with congestive heart failure, a slow heart rate and electrolyte disturbances, in particular low potassium, calcium or magnesium (tacrolimus SmPC, AEMPS, and label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The US ziprasidone label states that ziprasidone should not be given with QT-prolonging drugs and names tacrolimus on this list (ziprasidone label, US Food and Drug Administration, FDA). According to the Spanish summary of product characteristics (SmPC), ziprasidone should not be given with QT-prolonging drugs, and tacrolimus belongs to this group according to its own SmPC (ziprasidone and tacrolimus SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The tacrolimus documents are less strict: the Spanish SmPC advises caution with QT-prolonging drugs (tacrolimus SmPC, AEMPS). The US label advises considering periodic electrocardiograms (ECGs) and monitoring of magnesium, potassium and calcium with such drugs (FDA tacrolimus label). With other CYP3A4 substrates or inhibitors that can also prolong the QT interval, the US tacrolimus label recommends reducing the tacrolimus dose, monitoring tacrolimus blood levels frequently and watching for QT prolongation (FDA tacrolimus label). CYP3A4 is the main CYP enzyme that oxidises ziprasidone (ziprasidone SmPC, AEMPS, and label, FDA). Avoid tacrolimus in congenital long QT syndrome (FDA tacrolimus label). Ziprasidone is contraindicated in known QT prolongation, congenital long QT syndrome, recent acute myocardial infarction and uncompensated heart failure (ziprasidone SmPC, AEMPS). Correct low potassium and magnesium before starting ziprasidone, and in stable heart disease consider an ECG before starting. If the corrected QT interval (QTc) exceeds 500 ms, the SmPC recommends interrupting ziprasidone treatment (ziprasidone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica de Prograf 0,5 mg cápsulas duras (tacrolimus) (2026)– AEMPS, CIMA, nº registro 63189, secciones 4.4 y 4.5
- FDA: Prograf (tacrolimus) prescribing information (2025)– Astellas Pharma US. PROGRAF (tacrolimus) capsules, injection, granules. Prescribing information, DailyMed setid 7f667de1-9dfa-4bd6-8ba0-15ee2d78873b, sections 4, 5.11 and 7
- AEMPS: Ficha técnica: Zeldox (ziprasidona) (nº registro 64851), secciones 4.3 y 4.4 (2025)– AEMPS, CIMA, nº registro 64851, revisión 06/2025, secciones 4.3, 4.4 y 4.5
- FDA: Geodon (ziprasidone) prescribing information (2025)– FDA, DailyMed, setid a2b4cc65-6a6d-49c4-adfc-a4458562a167, Viatris Specialty, Revised 1/2025, sections 4.1, 5.3, 7.3